Tiny Biotech Scores Big With FDA-Approved Eye Drop
LENZ Therapeutics just got a major win. The FDA has officially approved their new eye drop, VIZZ, for treating presbyopia.
If you’ve never heard of it, presbyopia is the eye condition that makes it hard to see things up close, especially as you age. And now, there’s finally a drop for that.
This approval is kind of a big deal. It’s the first ever aceclidine-based eye drop approved in the US for this condition. Not only that, but LENZ got the thumbs up a week ahead of schedule, which doesn’t happen very often.
Why’s This Eye Drop So Special
VIZZ is based on an ingredient called aceclidine. The way it works is simple. It helps your pupils shrink just a bit to sharpen your near vision.
So instead of putting on reading glasses or squinting at your phone, one drop in each eye can help you see clearly for most of the day.
During testing, this drop was known as LNZ100. There was also another version being looked at, LNZ101, which had an extra ingredient. But in the end, LENZ went with the simpler formula using just aceclidine.
You’ll see the concentration listed as 1.44%, but that’s only because of how the FDA measures it. It’s actually the same formula as before, just written differently.
Using it is easy. Just one drop in each eye, then wait two minutes and add one more drop in each. That’s it for the whole day.
And good news for those who’ve had eye surgeries like LASIK or cataract. You might still be able to use VIZZ but check with your doctor first.
How’s LENZ Stock Doing?
LENZ isn’t wasting any time. They’ve already trained a full sales team and plan to start rolling out samples in October 2025. Full access should be available by the end of the year.
They’ve also locked in some big international deals, pulling in over $195 million just in upfront and milestone payments. On top of that, they’ll earn royalties from global sales.
The stock is currently sitting at $29.96, with an earnings-per-share of -1.63. While that’s not unusual for a small-cap biotech, the FDA approval could give it a major boost.
Investors are now watching to see how earnings shape up over the next few quarters.
So What’s Next
This is more than just a win for LENZ. It’s a big moment for biotech in general. FDA approvals are a key trigger for stock growth, especially in smaller companies.
If you’re following biotech trends or just learning how these things work, LENZ is worth keeping on your radar. They’re moving fast, and VIZZ could be the product that changes the game for them.
